Document Detail


Long-term effectiveness and safety of liraglutide in clinical practice.
MedLine Citation:
PMID:  23435446     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Aim: The rising adoption of liraglutide in clinical practice calls for an update on its long-term effectiveness and safety. The aims of this paper were to review characteristics of patients treated with liraglutide under routine clinical practice conditions, to describe therapeutic schemes, to assess the durability of liraglutide after two years of therapy, to evaluate changes in clinical parameters obtained after 20-24 months and to identify elective phenotype of patients that are able to respond better to this treatment. Methods: One diabetes outpatient clinic in Italy systematically collected data of patients receiving liraglutide every four months during a two-year follow-up. Mean levels and changes vs. baseline of HbA1c, fasting blood glucose (FBG), body weight, body mass index, waist circumference, blood pressure and lipid profile were evaluated. Rate of treatment discontinuation and side effects were also investigated. Results: Overall, 205 patients were analyzed. Liraglutide was prescribed as an add-on drug in 39% of patients and as a replacement in 61%. It was used both in patients with short (21% ≤5 years) and long (32% >15 years) diabetes duration and both in obese and non-obese individuals (38% BMI≤30 Kg/m2). Liraglutide was used within many different therapeutic schemes, also including insulin (20%). On average, HbA1c levels were reduced of 1% vs. baseline at each visit, but magnitude of reduction was inversely related to diabetes duration, i.e., to the preservation of beta-cell function. However, clinically relevant improvements of glycaemic control were obtained and sustained during two years in all subgroups of patients, despite of classes of diabetes duration, BMI and antidiabetic therapeutic regimen. Durability of effectiveness on body weight and waist circumference was also documented. Liraglutide treatment was also associated with a reduction of systolic blood pressure and improvement of lipid profile. Side effects, that occurred in 20% of patients during the first four months of treatment, decreased at 2% at 20 months. The rate of drop-out was 16.1% of the patients treated. Conclusion: The analysis of our clinical practice shows that treatment with liraglutide was safe, well tolerated and effective in reducing HbA1c, fasting blood glucose and body weight significantly, with positive effects on systolic blood pressure and lipid profile. Therefore, results of LEAD studies are substantially reproduced in the context of routine clinical practice. Even if the maximum effectiveness of liraglutide occurs in patients with short disease duration, preferably treated with metformin, also in patients with long duration of disease, treated with several drugs or in insulin therapy, the use of this GLP-1 analogue allows to obtain more than satisfactory results. Improvements in metabolic control and body weight are maintained after two years, suggesting durability and safety of liraglutide in the long run.
Authors:
P Ponzani
Related Documents :
22964206 - Midterm impact of sleeve gastrectomy, calibrated with a 50-fr bougie, on weight loss, g...
6842216 - Prognostic indicators and the pattern of recovery of communication in aphasic stroke pa...
25075656 - The effect of glutamine and synbiotics on the healing of colonic anastomosis.
1575006 - Differences in the outcome of patients with tia versus minor stroke.
24603776 - Impact of prescription patterns on compliance with follow-up visits at an urban teachin...
22617916 - Latissimus dorsi tendon transfer for irreparable rotator cuff tears: a systematic review.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva endocrinologica     Volume:  38     ISSN:  0391-1977     ISO Abbreviation:  Minerva Endocrinol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406505     Medline TA:  Minerva Endocrinol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  103-12     Citation Subset:  IM    
Affiliation:
Unit of Diabetology and Metabolic Diseases, Genoa Local Health Unit 3, La Colletta Hospital, Arenzano, Genoa, Italy - paola.ponzani@asl3.liguria.it.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin therapy: unmet needs and new perspectives.
Next Document:  The 17?-hydroxysteroid dehydrogenase type 3 deficiency: a case report of an 18-year patient and revi...